Calliditas Therapeutics AB (publ) (CALT) Competitors $40.00 0.00 (0.00%) As of 05/20/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock CALT vs. PCVX, RYTM, KRYS, SRPT, PTCT, ACAD, CYTK, RNA, ZLAB, and SWTXShould you be buying Calliditas Therapeutics AB (publ) stock or one of its competitors? The main competitors of Calliditas Therapeutics AB (publ) include Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), Krystal Biotech (KRYS), Sarepta Therapeutics (SRPT), PTC Therapeutics (PTCT), ACADIA Pharmaceuticals (ACAD), Cytokinetics (CYTK), Avidity Biosciences (RNA), Zai Lab (ZLAB), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Calliditas Therapeutics AB (publ) vs. Vaxcyte Rhythm Pharmaceuticals Krystal Biotech Sarepta Therapeutics PTC Therapeutics ACADIA Pharmaceuticals Cytokinetics Avidity Biosciences Zai Lab SpringWorks Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Vaxcyte (NASDAQ:PCVX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, media sentiment, institutional ownership, risk, valuation, profitability and dividends. Does the MarketBeat Community believe in CALT or PCVX? Vaxcyte received 28 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 78.57% of users gave Vaxcyte an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% VaxcyteOutperform Votes5578.57% Underperform Votes1521.43% Which has more volatility & risk, CALT or PCVX? Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500. Comparatively, Vaxcyte has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Do insiders and institutionals believe in CALT or PCVX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 96.8% of Vaxcyte shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 3.1% of Vaxcyte shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is CALT or PCVX more profitable? Vaxcyte has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Vaxcyte's return on equity of -23.53% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Vaxcyte N/A -23.53%-22.20% Which has higher valuation & earnings, CALT or PCVX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Vaxcyte. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Vaxcyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62VaxcyteN/AN/A-$402.27M-$3.99-8.51 Do analysts rate CALT or PCVX? Calliditas Therapeutics AB (publ) currently has a consensus price target of $39.25, indicating a potential downside of 1.88%. Vaxcyte has a consensus price target of $136.50, indicating a potential upside of 301.83%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Does the media prefer CALT or PCVX? In the previous week, Vaxcyte had 15 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 15 mentions for Vaxcyte and 0 mentions for Calliditas Therapeutics AB (publ). Vaxcyte's average media sentiment score of 1.37 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Vaxcyte is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Vaxcyte Positive SummaryVaxcyte beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks. Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CALT vs. The Competition Export to ExcelMetricCalliditas Therapeutics AB (publ)Pharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.19B$6.49B$5.36B$8.39BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-21.628.9426.5919.72Price / Sales0.74251.55391.61116.20Price / CashN/A65.8538.2534.62Price / Book37.746.466.794.51Net Income-$43.96M$143.98M$3.23B$248.18M7 Day PerformanceN/A3.16%4.03%1.14%1 Month PerformanceN/A7.60%12.22%15.07%1 Year Performance86.05%-2.36%16.76%6.59% Calliditas Therapeutics AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180PCVXVaxcyte3.117 of 5 stars$32.03+0.6%$136.50+326.2%-51.8%$4.13BN/A-6.96160News CoveragePositive NewsEarnings ReportRYTMRhythm Pharmaceuticals3.9307 of 5 stars$61.25+2.2%$75.38+23.1%+63.9%$3.90B$136.86M-14.15140KRYSKrystal Biotech4.8578 of 5 stars$132.29+1.3%$211.13+59.6%-20.0%$3.82B$333.45M44.24210SRPTSarepta Therapeutics4.8078 of 5 stars$37.94+4.1%$124.36+227.8%-69.4%$3.73B$2.23B30.35840Positive NewsAnalyst ForecastGap UpHigh Trading VolumePTCTPTC Therapeutics4.2208 of 5 stars$46.96+2.1%$61.92+31.9%+17.6%$3.72B$1.77B-7.911,410ACADACADIA Pharmaceuticals3.3061 of 5 stars$21.99-1.2%$25.42+15.6%+43.6%$3.68B$996.28M28.19510Trending NewsAnalyst ForecastAnalyst RevisionGap UpHigh Trading VolumeCYTKCytokinetics4.1746 of 5 stars$30.75-0.8%$74.44+142.1%-46.1%$3.67B$19.22M-5.72250RNAAvidity Biosciences1.9492 of 5 stars$30.22-0.4%$66.38+119.7%+8.2%$3.64B$8.93M-10.49190Options VolumeZLABZai Lab2.6626 of 5 stars$32.99+6.7%$47.37+43.6%+56.6%$3.64B$418.33M-11.911,950SWTXSpringWorks Therapeutics2.3615 of 5 stars$46.27+0.3%$52.57+13.6%+9.1%$3.49B$219.67M-13.30230Positive News Related Companies and Tools Related Companies Vaxcyte Alternatives Rhythm Pharmaceuticals Alternatives Krystal Biotech Alternatives Sarepta Therapeutics Alternatives PTC Therapeutics Alternatives ACADIA Pharmaceuticals Alternatives Cytokinetics Alternatives Avidity Biosciences Alternatives Zai Lab Alternatives SpringWorks Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CALT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calliditas Therapeutics AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Calliditas Therapeutics AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CALT Stock Free CALT Stock Alerts